tbuckley/cabot-search huggingface dataset:
Abstract 3493: Epidemiology and Genetic Cause of Sudden Unexplained Nocturnal Death Syndrome in Southern China
Authors: Jian-Ding Cheng, Nian-Qing Shi, Jonathan Makielski, Bin Ye
Journal: Circulation (2007)

Sudden unexplained nocturnal death syndrome (SUNDS) is a sleep disorder that leads to sudden cardiac death in Southeast Asian ethnic groups such as Thai, Japanese, Philippine and Cambodian. SUNDS mainly occurs during sleep in young healthy males without sign of cardiac dysfunction. The lack of epidemiologic data is always being a formidable bottleneck for studying SUNDS around the world. Although the annual occurrence rate of SUNDs is high (over 2/100,000) for the aged 20 to 40 years males in Southern China, the disease epidemiology in regions of China may be underestimated in the absence of systemic monitoring. Autopsy data collected in Guangdong Province (a Southern China province) from 2001–2006 reported 975 cases of SUNDS. Among the victims, 93.2% were males while 6.8% were females. In 772 cases with complete medical records, 86.3% deaths occurred between ages 16 to 40. The peak months for SUNDS occurrence were April (111 cases), May (112 cases) and June (80 cases), which corresponded to highest numbers of fever patients in this period indicating that fever may play a role in SUNDS. In 75.4% cases where witnesses were present, victims died in sleep between 11 PM to 4 AM and showed signs that matched reported cases in other Southeast Asian populations. Other collected data included birthplace and profession and details of events at death. The genetic cause of Chinese SUNDS is being investigated more recently. Mutations in the voltage-gated sodium channel ( SCN5A ) have been linked to SUNDS. We traced four generations in two families with SUNDS history and in each case, diseased male victims in the second and third generations at the age of 17–38 were found. Surviving relatives did not show any significant cardiac structural defects but their ECGs displayed an abnormal Q wave or sinus bradycardia in male siblings who approached age 30. Mutation screening in the SCN5A gene using specimen obtained from diseased victims and survived relatives was undertaken to identify SUNDS-related mutations in these two families. This is the first report of SUNDS epidemiology and its impact in the Han population of Southern China.
Error in Discussion Section
Authors: Anca Radulescu, Nadia Radu, Alexandra Preda, Carmen Iuga, Mariana Dinu, Iuliana Dobre, Florin Tibu, Bogdan Simon, Mark Wade
Journal: JAMA Psychiatry (2019)

Gabriella Gobbi, MD, PhD; Tobias Atkin, BA; Tomasz Zytynski, MD; Shouao Wang, MSc; Sorayya Askari, PhD; Jill Boruff, MLIS; Mark Ware, MD, MSc; Naomi Marmorstein, PhD; Andrea Cipriani, MD, PhD; Nandini Dendukuri, PhD; Nancy Mayo, PhD
Head Injury
Authors: Julian T. Hoff
Journal: JAMA (1981)

Nearly ten years have passed since the last handbook on head injury was published. During that interval, interest in the subject has increased substantially, and clinical and surgical management and methods for evaluating prognosis for patients with head injury have changed. The 27 concise, well-organized chapters are based on the clinical experience of two scholarly neurosurgeons. Topics such as intracranial pressure dynamics, new radiological techniques for diagnosis (including the computed tomographic scanner), and methods used to predict outcome are discussed in detail. The chapters on intracranial hemorrhage, cranial nerve injuries, and the vascular complications of head trauma are especially good, and the chapter on the legal aspects and ramifications of treating this patient group is interesting and timely. The book is well written and nicely illustrated. Unfortunately, the references are highly selective, and only one of the several hundred cited was published during the past two years. Thus, the volume
Galanthamine
Authors: Erkki Toivakka
Journal: JAMA (1978)

<h3>To the Editor.—</h3> We were delighted to read that Baraka and Harik (238:2293, 1977) found that galanthamine hydrobromide was able to reverse the central anticholinergic syndrome in volunteers. This confirms the finding here in the clinical situation that this drug is an effective antidote in a case of scopolamine intoxication.<sup>1</sup>The effect of galanthamine hydrobromide on the disruption of behavior provoked by central anticholinergics had been reported from the Soviet Union in 1969.<sup>2</sup> Baraka and Harik quote evidence that galanthamine hydrobromide produces substantial EEG effects, but in our experience the drug, administered to normal<sup>3</sup>and epileptic<sup>4</sup>volunteers, only gave slight to mild changes in the EEG pattern. The duration of the change following an intravenous dose of 20 mg was up to 30 minutes. Galanthamine, like edrophonium, is a reversible type of anticholinesterase.<sup>5</sup>Unfortunately, it is not available generally except in Eastern Europe. The long duration
Preliminary results of a multicenter phase II trial of neoadjuvant docetaxel, carboplatin and capecitabine for inflammatory and locally advanced breast cancer (LABC)
Authors: S. X. Franco, A. Perez, C. Frankel, E. Tan-Chiu, L. Schwartzberg, M. Schwartz, E. Krill, J. Jakub, N. Abramson, C. Vogel
Journal: Journal of Clinical Oncology (2005)

876 Background: Neoadjuvant chemotherapy for the treatment of LABC has become the standard of care but the best combination has not yet been established. The combination of docetaxel and capecitabine has demonstrated synergism in patients with metastatic breast cancer (MBC) and recent studies have demonstrated the value of platinum salts in LABC and MBC. Methods: We are evaluating the combination of weekly docetaxel 30mg/m2, carboplatin AUC 2 on D1, 8,15 out of a 4-week cycle plus capecitabine 625 mg/m2 twice/day given on days 5–18 (based on the upregulation of thymidine phosphorylase) given for 4 cycles prior to surgery. Adjuvant therapy consisted of Adriamycin/Cytoxan for 4 cycles, radiation therapy +/- hormonal therapy. Results: Currently, 24 patients have been enrolled, median age is 49 (range 28–75) with clinical stages ranging from IIb-IIIb. Seventeen patients are evaluable for toxicity. A total of 1173 doses(including daily capecitabine) have been administered out of 1280 planned (92% of intended dose). There were 7 dose delays and 2 dose reductions. No grade IV toxicities were seen, grade III neutropenia was seen in 3/17(17%) and grade III fatigue in 1/17(5%). There were no episodes of neutropenic fever.The most common grade I/II toxicities were nausea in 58%, diarrhea 41%, fatigue 41%, epiphora 29%, mucositis 29% and hand-foot syndrome 6%. No treatment related deaths have been reported. Sixteen patients have completed definitive surgery with tumor sizes ranging from 2.5 to 15cm (median 5.5cm). One patient had Inflammatory BC and 9 had N2 disease. Nine tumors were ER+, 7 ER- and 4 Her-2 +. Objective response rate was 93% with 62% cCR. Four patients had pCRs in breast and axilla(25%) and 2 patients had microscopic residual disease in the breast (1mm). Six patients had complete axillary clearance (37%). Conclusions: The preoperative combination of docetaxel, carboplatin and capecitabine is feasible with a good response rate and an acceptable toxicity profile. Active enrollment continues. No significant financial relationships to disclose.
THE ACTION OF THE X-RAYS IN LEUKEMIA.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Retraction: Insulin-Like Growth Factor I Suppresses Bone Morphogenetic Protein Signaling in Prostate Cancer Cells by Activating mTOR Signaling
Authors: Reema S. Wahdan-Alaswad, Kyung Song, Tracy L. Krebs, Dorjee T.N. Shola, Jose A. Gomez, Shigemi Matsuyama, David Danielpour
Journal: Cancer Research (2020)

This article (1) is being retracted at the request of the corresponding author. Errors were found in Figs. 1A, 3C, and 4D that diminish the reliability of this study. In Fig. 1A, the Western blot image for β-actin was an erroneous duplication of the image for Smad2 in both the right and left panels. In addition, the original Western blot data for Smad3 and Smad 1/5/8 could not be identified. In Fig. 3C, the Western blot image for Smad1/5/8 on the left was found to be a duplication of Smad1/5/8 on the right; the original data do not specify which of the two figures it is associated with. In Fig. 4D, the Western blot image for P-Smad1/5/8 (Ab#2) on the right was found to be a different exposure of P-Smad1/5/8 (Ab#1) on the left. In addition, the original data for Smad 1/5/8 could not be identified. The authors apologize to the scientific community and deeply regret any inconveniences or challenges resulting from the publication and subsequent retraction of this article.A copy of this retraction notice was sent to the last known e-mail addresses for all seven authors. Five authors (K. Song, D.T.N. Shola, J.A. Gomez, S. Matsuyama, and D. Danielpour) agreed to the retraction; one author (R.S. Wahdan-Alaswad) did not agree to the retraction; and one author (T.L. Krebs) did not respond.
Seven honored for tracking disorders to genetic source
Authors: B. Merz
Journal: JAMA (1982)

The 1982 Albert Lasker Memorial Awards for Medical Research were presented to seven investigators at a recent luncheon in New York City. Five of the scientists shared the $15,000 award for basic research, and two the equal award for clinical research. The basic research awards were presented to J. Michael Bishop, MD; Harold E. Varmus, MD; Hidesaburo Hanafusa, PhD; Raymond L. Erikson, PhD; and Robert C. Gallo, MD, for their "revolutionary discoveries" of the human genes known as oncogenes "which have provided a long-sought link between viruses and the development of cancer." The recipients of the clinical research award, Roscoe O. Brady, MD, and Elizabeth F. Neufeld, PhD, were cited for their "original and creative contributions to the understanding of two groups of inherited [enzymedeficiency] diseases—lipid storage diseases and mucopolysaccharide storage disorders." <h3>The Oncogene Investigators</h3> Bishop, 46, and Varmus, 43, both professors of microbiology, University of California School of Medicine,
Too few human organs for transplantation, too many in need . . . and the gap widens
Authors: T. Randall
Journal: JAMA (1991)

THE ORGAN SHORTAGE problem has been called "a public health crisis with a cure." Each year, however, the "crisis" becomes more critical, and the "cure," although supported in concept by health professionals and the American public, loses ground in practice. In the last few years, organ donation has leveled off and even decreased for some organs. At the same time, the waiting list for organ transplantation has been increasing by thousands of individuals each year. As lengthy as this list may be, it represents only a fraction of the actual numbers of people who could be rehabilitated with an organ transplant. As of a month ago, 22 340 individuals were waiting for a transplant; of these, 18 163 were waiting for a kidney. And yet in 1989 (the most recent year for which transplantation statistics are available), just 8905 kidney transplants were performed—7063 from cadaveric donors and 1842 from living-related
Useful Drugs: A List of Drugs Selected to Supply the Demand for a Less Extensive Materia Medica with a Brief Discussion of Their Actions, Uses and Dosage
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Officials of the Association
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Why First-Line Nivolumab Is No Better than Chemo
Journal: Cancer Discovery (2017)

In a recent trial, the PD-1 inhibitor nivolumab failed to outperform chemotherapy as a first-line treatment for non-small cell lung cancer, even though another PD-1 inhibitor, pembrolizumab, was shown to be an effective treatment just months earlier. Researchers attribute these surprising results to differences in patient selection in the two trials, and suggest that the discovery of better biomarkers, among other strategies, might allow more patients to benefit from immunotherapies.
In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines.
Authors: H. Cheng, Y. Wu, S. An, X. Zhang, S. Dong, Y. Zhang
Journal: Journal of Clinical Oncology (2010)

e21109 Background: Clinical trials showed that the epidermal growth factor receptor tyrosine kinase inhibitior (EGFR-TKI) combined with first-line cytotoxicity chemotherapy concomitantly didn't confer a survival benefit in non-small cell lung cancer (NSCLC). The aim of this study is to test whether paclitaxel followed by gefitinib would be superior to the other schedules in NSCLC cell lines and the underlying mechanisms of them. Methods: we have used human lung cancer cell lines with wild type and mutant type EGFR gene as an in vitro model for defining the differential effects of various schedules of pacitaxel with gefitinib on cell growth, signaling pathway and cell cycle distribution. Results: Only the sequence of paclitaxel followed by gefitinib in A549, H1975 and PC-9 cells produced synergistic effects in all of the drug concentrations. Exposure to paclitaxel resulted in an increased pEGFR level, this increase of phosphorylation can be inhibited by the following gefitinib exposure, while the reverse sequence the inhibition effect was inferior. Higher level EGFR activation were observed in mitotic cells than interphase cells after paclitaxel exposure. We confirmed that gefitinib arrested the cells in G1, paclitaxel arrested cells in S phase. The sequence of paclitaxel followed by gefitinib caused cells arrested in G1, while the reverse sequence caused cells arrested in S and G2 phase. Conclusions: These findings suggest that the sequence of paclitaxel followed by gefitinib may be superior to the other sequences in NSCLC cell lines. The results also provided the basic evidence of clinical treatment strategies for patients with lung cancer. No significant financial relationships to disclose.
Stimulant medications in Tourette's syndrome
Journal: JAMA (1982)

<h3>In Reply.—</h3> Use of stimulant medica tion in the treatment of ADD in children should be in the context of an intervention strategy that often includes other modalities (such as parent guidance, behavior modification, special education, and psychotherapy). At present, there is no method for predicting which child will benefit from administration of stimulants, and a carefully monitored clinical "trial" may be warranted. However, stimulants are not without risk, and should not be used with all hyperactive children. For example, some severe disorders in children, such as autism, may worsen dramatically with only one or several doses, and continued use of stimulants may be catastrophic. The patients we described with Tourette's syndrome precipitated by stimulants, and others we have studied subsequently, received medication in the usual therapeutic range (eg, 15 to 60 mg/day of methylphenidate
Torsion of the appendix testis. Report of 13 cases
Authors: H. B. Simon
Journal: JAMA (1967)

Torsion of the appendix testis is not an uncommon cause of scrotal pain and swelling, and is frequently misdiagnosed as epididymitis or orchitis. The etiology remains obscure. Prompt surgical intervention is warranted almost without exception, to both rule out the more serious possibility of torsion of the spermatic cord, and for prompt relief of the symptoms and local tissue reaction which result in obstructed fertility of the affected testis.
Words
Authors: Frank Brennan
Journal: Annals of Internal Medicine (2007)

On Being a Doctor20 March 2007WordsFrank Brennan, MBBSFrank Brennan, MBBSFrom Calvary Hospital, Kogarah, Sydney, New South Wales 2217, Australia.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-146-6-200703200-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail I met her at the main hospital. She had metastatic colorectal cancer and had received extensive chemotherapy. Her disease had progressed, and her options were rapidly diminishing. She was becoming thinner. I talked to her about palliative care and what the hospice had to offer. She agreed to come over to the inpatient hospice unit.Later that week I saw her there. She was in a single room. She lay weakly. The bed covers seemed too big for her. Her mouth was dry. She spoke slowly. After discussing her symptoms I said that I thought her time was approaching. She ... Author, Article, and Disclosure InformationAffiliations: From Calvary Hospital, Kogarah, Sydney, New South Wales 2217, Australia.Corresponding Author: Frank Brennan, MBBS, Calvary Hospital, Kogarah, Sydney, New South Wales 2217, Australia; e-mail, [email protected]com.au. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 20 March 2007Volume 146, Issue 6Page: 464KeywordsBreathingChemotherapyColorectal cancerHeartInpatientsMotivationMouthPalliative care ePublished: 20 March 2007 Issue Published: 20 March 2007 Copyright & PermissionsCopyright © 2007 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Miscellany
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal